These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1156 related items for PubMed ID: 19781407

  • 1. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
    Zhao SP, Peng DQ, Yu BL, Huo Y, CHILLAS investigators.
    Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
    [Abstract] [Full Text] [Related]

  • 2. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E.
    J Am Coll Cardiol; 2009 Dec 15; 54(25):2358-62. PubMed ID: 20082923
    [Abstract] [Full Text] [Related]

  • 3. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP, TIMI Study Group.
    J Am Coll Cardiol; 2009 Dec 08; 54(24):2290-5. PubMed ID: 19958964
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J.
    Am J Med; 2005 Dec 08; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
    Leone AM, Rutella S, Giannico MB, Perfetti M, Zaccone V, Brugaletta S, Garramone B, Niccoli G, Porto I, Liuzzo G, Biasucci LM, Bellesi S, Galiuto L, Leone G, Rebuzzi AG, Crea F.
    Int J Cardiol; 2008 Nov 28; 130(3):457-62. PubMed ID: 18667247
    [Abstract] [Full Text] [Related]

  • 12. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
    Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ.
    Am J Cardiol; 2007 Mar 01; 99(5):632-5. PubMed ID: 17317362
    [Abstract] [Full Text] [Related]

  • 13. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May 01; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 14. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
    Deedwania PC, Study Assessing Goals in the Elderly steering committee and investigators.
    Am Heart J; 2004 Dec 01; 148(6):1053-9. PubMed ID: 15632893
    [Abstract] [Full Text] [Related]

  • 15. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis.
    Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP, TIMI 22 Investigators.
    Am Heart J; 2008 May 01; 155(5):954-8. PubMed ID: 18440347
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
    Austin PC, Mamdani MM.
    Circulation; 2005 Aug 30; 112(9):1296-300. PubMed ID: 16116054
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.